A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Trial Profile

A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TONES 4
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 19 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Results from this trial published in a Jazz Pharmaceuticals Media Release.
    • 06 Jun 2017 According to a Jazz PHarmaceuticals media release, were presented at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top